| Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.J Clin Oncol | PMID 36166727PMC9839305 | 2023-Jan-10 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study.J Clin Oncol | PMID 36265101无 PMCID | 2023-Jan-10 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial.J Clin Oncol | PMID 36332179PMC9839304 | 2023-Jan-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial.Crit Care | PMID 36627655PMC9830601 | 2023-Jan-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A randomized phase 3 trial to assess the immunogenicity and safety of 3 consecutively produced lots of freeze-dried MVA-BN® vaccine in healthy adults.Vaccine | PMID 36460535PMC9707699 | 2023-Jan-09 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Costs of delivering human papillomavirus vaccination using a one- or two-dose strategy in Tanzania.Vaccine | PMID 36460537PMC9831118 | 2023-Jan-09 | 0.80 | Although the record is a Phase III randomized controlled trial on an oncology-related topic (HPV vaccination for cervical cancer prevention), it exclusively reports cost outcomes (financial and economic costs per dose). It does not report any clinical efficacy outcomes such as survival, progression, recurrence, death, or time-to-event measures. The deterministic review signal of 'no_outcome_signal' is correct. | 待处理 |
| Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.Lancet | PMID 36442484无 PMCID | 2023-Jan-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).Lancet | PMID 36493791无 PMCID | 2023-Jan-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).Lancet | PMID 36495881无 PMCID | 2023-Jan-07 | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 待处理 |
| Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial.Clin Infect Dis | PMID 36068705PMC9825827 | 2023-Jan-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial.Clin Infect Dis | PMID 36069202PMC9825825 | 2023-Jan-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial.Neuro Oncol | PMID 35419607PMC9825306 | 2023-Jan-05 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Hippocampal avoidance prophylactic cranial irradiation (HA-PCI) for small cell lung cancer reduces hippocampal atrophy compared to conventional PCI.Neuro Oncol | PMID 35640975PMC9825336 | 2023-Jan-05 | 0.80 | This is a Phase III randomized controlled trial report on small cell lung cancer. It meets criteria for oncology, human subjects, randomized design, and definitive phase. However, the outcomes measured (hippocampal atrophy, brain injury, memory decline) are neurotoxicity and quality-of-life related, not the survival, progression, recurrence, death, hazard, or time-to-event efficacy outcomes required for inclusion in the KM digitization cohort. | 待处理 |
| Lecanemab in Early Alzheimer's Disease.N Engl J Med | PMID 36449413无 PMCID | 2023-Jan-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay.Vaccine | PMID 36404171PMC9671637 | 2023-Jan-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Transfusion use and effect on progression-free, overall survival, and quality of life in upfront treatment of advanced epithelial ovarian cancer: evaluation of the European Organization for Research and Treatment EORTC-55971 Cohort.Int J Gynecol Cancer | PMID 36356982PMC10046328 | 2023-Jan-03 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Cost-effectiveness of Novel Macrophage-Regulating Treatment for Wound Healing in Patients With Diabetic Foot Ulcers From the Taiwan Health Care Sector Perspective.JAMA Netw Open | PMID 36633847PMC9856772 | 2023-Jan-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas: A Randomized Clinical Trial.JAMA Netw Open | PMID 36705923PMC11839150 | 2023-Jan-03 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer.J Clin Oncol | PMID 35858154PMC9788977 | 2023-Jan-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH).J Clin Oncol | PMID 35921605无 PMCID | 2023-Jan-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Pexidartinib Provides Modest Pain Relief in Patients With Tenosynovial Giant Cell Tumor: Results From ENLIVEN.Clin Orthop Relat Res | PMID 36001000PMC9750631 | 2023-Jan-01 | 0.95 | The study meets oncology, human, randomized, phase 3, and drug intervention criteria, but fails the key time-to-event efficacy endpoint criterion. The primary endpoint was pain relief (a numeric rating scale), not a survival or progression endpoint. | 待处理 |
| Examining the Effect of Direct Patient Care for Medical Physicists: A Randomized Prospective Phase III Trial.Int J Radiat Oncol Biol Phys | PMID 36289039无 PMCID | 2023-Jan-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effects of Disease-Worsening Following Withdrawal of Etanercept or Methotrexate on Patient-Reported Outcomes in Patients With Rheumatoid Arthritis: Results From the SEAM-RA Trial.J Clin Rheumatol | PMID 36459119PMC9803379 | 2023-Jan-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tolvaptan for Children and Adolescents with Autosomal Dominant Polycystic Kidney Disease: Randomized Controlled Trial.Clin J Am Soc Nephrol | PMID 36719158PMC10101612 | 2023-Jan-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Celecoxib-tramadol co-crystal in patients with moderate-to-severe pain following bunionectomy with osteotomy: A phase 3, randomized, double-blind, factorial, active- and placebo-controlled trial.Pain Pract | PMID 35686380PMC10084286 | 2023-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.J Am Acad Dermatol | PMID 35820547无 PMCID | 2023-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Early Ultrasound Response and Progressive Transmural Remission After Treatment With Ustekinumab in Crohn's Disease.Clin Gastroenterol Hepatol | PMID 35842121无 PMCID | 2023-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 study.Cancer Med | PMID 35848358PMC9883440 | 2023-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A Double-Blind Randomized Placebo-Controlled Phase 3 Trial of Tobramycin Inhalation Solution in Adults With Bronchiectasis With Pseudomonas aeruginosa Infection.Chest | PMID 35863486无 PMCID | 2023-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA).J Hepatobiliary Pancreat Sci | PMID 35900311PMC10086809 | 2023-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial.Ann Rheum Dis | PMID 35961761PMC9811076 | 2023-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Placement of an intrauterine device within 48 hours after early medical abortion-a randomized controlled trial.Am J Obstet Gynecol | PMID 35970199无 PMCID | 2023-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of tezepelumab in patients recruited in Japan who participated in the phase 3 NAVIGATOR study.Allergol Int | PMID 35977863无 PMCID | 2023-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial.Gastric Cancer | PMID 36066725PMC9813086 | 2023-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.J Am Acad Dermatol | PMID 36115523无 PMCID | 2023-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impact of Early Dorsal Venous Complex Ligation on Urinary Continence Recovery after Robot-assisted Radical Prostatectomy: Results from a Phase 3 Randomized Controlled Trial.Eur Urol Focus | PMID 36154808无 PMCID | 2023-Jan | 0.95 | The record describes a randomized Phase III trial with a time-to-event endpoint, but the intervention is a surgical technique, not a drug-containing intervention. Therefore, it does not meet the eligibility criterion for a drug-containing intervention. | 待处理 |
| Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: Overall survival from MONARCH 2.Cancer Sci | PMID 36168844PMC9807498 | 2023-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel versus Umbilical Cord Blood.Transplant Cell Ther | PMID 36179986PMC9825638 | 2023-Jan | 0.85 | The study is a randomized phase 3 trial in human hematologic malignancies, but it is excluded because it reports on a quality-of-life endpoint, not a primary/key secondary time-to-event efficacy endpoint, and the intervention is a cellular therapy, not a drug-containing intervention. | 待处理 |
| Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial.J Thorac Oncol | PMID 36184068无 PMCID | 2023-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study.Epilepsia | PMID 36196777PMC10099582 | 2023-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2-T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase III trial (the TAU-TEM study).Ann Oncol | PMID 36220461无 PMCID | 2023-Jan | 0.45 | The trial is a randomized Phase III oncology study in humans, but the abstract reports only short-term morbidity and pathological outcomes. It explicitly states that cancer outcome results (which would include time-to-event endpoints) are pending. The intervention includes chemoradiotherapy, but the trial's primary comparison is between two surgical strategies (local excision vs. total mesorectal excision), and the abstract does not present the time-to-event efficacy data required for inclusion. | 待处理 |
| Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial.Lancet Gastroenterol Hepatol | PMID 36240801无 PMCID | 2023-Jan | 0.85 | This is a randomized, Phase 3 trial of a drug (etrolizumab) with original results, but it is not an oncology trial; it studies Crohn's disease. Furthermore, its primary endpoints are not time-to-event (Kaplan-Meier, HR, etc.) but are clinical remission and endoscopic improvement at fixed timepoints. | 待处理 |
| NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC.J Thorac Oncol | PMID 36240972无 PMCID | 2023-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.Lancet Respir Med | PMID 36252599无 PMCID | 2023-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Lower injection-site reactions and long-term safety, immunogenicity, and efficacy of etanercept biosimilar YLB113: Results from a post-hoc analysis of a double-blind, randomized, phase III comparative study and its open-label extension in patients with rheumatoid arthritis.Int J Rheum Dis | PMID 36253032PMC10092464 | 2023-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies.Am J Clin Dermatol | PMID 36264430PMC9870821 | 2023-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up.Adv Ther | PMID 36272026PMC9589670 | 2023-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Patient-Centered Perspective of Molluscum Contagiosum as Reported by B-SIMPLE4 Clinical Trial Patients and Caregivers: Global Impression of Change and Exit Interview Substudy Results.Am J Clin Dermatol | PMID 36287306PMC9870829 | 2023-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| AbobotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity regardless of spinal cord injury or multiple sclerosis etiology: Pooled analysis of two phase III randomized studies (CONTENT1 and CONTENT2).Neurourol Urodyn | PMID 36321799PMC10092111 | 2023-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.J Hepatol | PMID 36341767无 PMCID | 2023-Jan | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |